Jinyu Bio-Technology Co Ltd Asset Resilience Ratio
Jinyu Bio-Technology Co Ltd asset resilience ratio. Jinyu Bio-Technology Co Ltd (600201) has an Asset Resilience Ratio of 0.92% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Jinyu Bio-Technology Co Ltd (600201) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jinyu Bio-Technology Co Ltd (2016–2025)
Asset resilience ratio of Jinyu Bio-Technology Co Ltd from 2016 to 2025. This chart shows how Jinyu Bio-Technology Co Ltd's Asset Resilience Ratio has changed over time. Read Jinyu Bio-Technology Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jinyu Bio-Technology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 600201 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥61.15 Million | 0.92% |
| Total Liquid Assets | CN¥61.15 Million | 0.92% |
Asset Resilience Insights
- Limited Liquidity: Jinyu Bio-Technology Co Ltd maintains only 0.92% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jinyu Bio-Technology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jinyu Bio-Technology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Jinyu Bio-Technology Co Ltd Asset Resilience Ratio by Year (2016–2025)
Jinyu Bio-Technology Co Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Jinyu Bio-Technology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.82% | CN¥120.11 Million ≈ $17.58 Million |
CN¥6.61 Billion ≈ $967.48 Million |
+1.27pp |
| 2024-12-31 | 0.54% | CN¥36.83 Million ≈ $5.39 Million |
CN¥6.76 Billion ≈ $989.88 Million |
+0.00pp |
| 2023-12-31 | 0.54% | CN¥37.27 Million ≈ $5.45 Million |
CN¥6.87 Billion ≈ $1.01 Billion |
-0.19pp |
| 2022-12-31 | 0.73% | CN¥46.94 Million ≈ $6.87 Million |
CN¥6.39 Billion ≈ $934.96 Million |
-2.05pp |
| 2021-12-31 | 2.78% | CN¥183.85 Million ≈ $26.90 Million |
CN¥6.60 Billion ≈ $966.36 Million |
-7.40pp |
| 2020-12-31 | 10.19% | CN¥639.48 Million ≈ $93.58 Million |
CN¥6.28 Billion ≈ $918.71 Million |
-1.85pp |
| 2019-12-31 | 12.04% | CN¥672.48 Million ≈ $98.40 Million |
CN¥5.59 Billion ≈ $817.39 Million |
-0.63pp |
| 2018-12-31 | 12.67% | CN¥800.00 Million ≈ $117.07 Million |
CN¥6.31 Billion ≈ $923.82 Million |
-1.40pp |
| 2017-12-31 | 14.08% | CN¥800.00 Million ≈ $117.07 Million |
CN¥5.68 Billion ≈ $831.69 Million |
+8.05pp |
| 2016-12-31 | 6.03% | CN¥262.00 Million ≈ $38.34 Million |
CN¥4.35 Billion ≈ $636.21 Million |
-- |
About Jinyu Bio-Technology Co Ltd
Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary biological products in China and internationally. The company's products focus on preventing porcine mycoplasmal pneumonia, pseudorabies, highly pathogenic avian influenza, brucellosis, and other Class I, II, and III animal diseases. It also provides pig vaccines, swine foot-and-mouth diseas… Read more